Prostate Cancer 

Last Updated:

Focused ultrasound treatment for the prostate is available in the United States.

Three focused ultrasound systems for destroying diseased prostate tissue are approved by the Food and Drug Administration. In addition, Medicare has taken initial steps to cover this treatment, which will hopefully impact the commercial carriers to do the same.

Focused Ultrasound Therapy

Focused ultrasound is a noninvasive, radiation-free method to destroy prostate tissue and treat prostate disease. Using real-time image guidance, the physician directs a focused beam of ultrasound energy to a selected volume in the patient’s prostate gland.

How it Works
Focused ultrasound energy heats and destroys the targeted tissue at the focal point within seconds. This process is repeated until the entire selected volume or the entire gland is destroyed.

Advantages
The primary options for treatment of prostate cancer include the avoidance of invasive procedures that may include ionizing radiation and surgery.

Focused ultrasound is a low-morbidity treatment that usually only requires a single therapy session and has a short recovery time. It is reported to have a low complication rate, especially when considering post-procedure impotence and incontinence. Focused ultrasound treatment does not use ionizing radiation, and it is possible to offer it as a salvage therapy for patients who fail radiation treatment. Focused ultrasound treatment can be a complement to drug therapy, enabling enhanced delivery of chemotherapy or immunotherapy to tumors, and it may potentially induce an anti-tumor immune response.

Clinical Trials

A registry for the TULSA-PRO is tracking patient outcomes for this device. 

A clinical trial in Norway is comparing HIFU to active surveillance. 

A clinical trial in the US is a randomized trial comparing the TULSA PRO to radical prostatectomy. 

See a full list of prostate cancer clinical trials > 

See a list of treatment sites >
See a list of clinical trials sites >
See a list of laboratory research sites >

Regulatory Approval and Reimbursement

Focused ultrasound devices have been cleared to treat the prostate in approximately 50 countries, including the United States. Several systems for focused ultrasound ablation of prostate tissue are available in various geographical regions, each differing in their guidance method (ultrasound vs. magnetic resonance imaging) and approach – transrectal or transurethral.

While the Foundation attempts to keep the list of sites complete, there have been many purchases of the focused ultrasound systems. For the latest information on availability, we recommend contacting the manufacturers’ directly or using their online search functions. 

There are four focused ultrasound manufacturers that are approved in the US for the ablation (destruction) of prostate tissue – Sonablate Corp.,  EDAP-TMSProfound Medical, and Insightec. Sonablate and EDAP deliver care outside of the MRI facility, so they are found in surgery centers and surgical suites, as well as in hospitals. 

There are additional sites that use mobile focused ultrasound equipment. These sites may not be listed on the EDAP, Sonablate, or Profound Medical sites, and the best way to find them is to contact local urologists to see if they have focused ultrasound capability.

Reimbursement for primary treatment in the US has been lagging, and Medicare and most insurance companies are either covering a portion of the expense or not covering it at all. In the specific instance of salvage therapy after failed radiation, some Medicare providers and commercial insurance carriers are covering focused ultrasound use in this setting. As always, it is best to check with your specific carrier.

Notable Papers 

Suggested Reading: Focused Ultrasound for Prostate Cancer Case Study (2021)

Silva PALD, Lima AFC. Direct costs of treating men with prostate cancer with High Intensity Focused Ultrasound. Rev Esc Enferm USP. 2023 Nov 27;57:e20230132. doi: 10.1590/1980-220X-REEUSP-2023-0132en. eCollection 2023. PMID: 38009909 

Mala KS, Plage H, Mödl L, Hofbauer S, Friedersdorff F, Schostak M, Miller K, Schlomm T, Cash H. Follow-Up of Men Who Have Undergone Focal Therapy for Prostate Cancer with HIFU-A Real-World Experience. J Clin Med. 2023 Nov 14;12(22):7089. doi: 10.3390/jcm12227089. PMID: 38002699 

Saouli A, Ruffion A, Dariane C, Barret E, Fiard G, Hankard GF, Créhange G, Roubaud G, Beauval JB, Brureau L, Renard-Penna R, Gauthé M, Baboudjian M, Ploussard G, Rouprêt M. Salvage Radical Prostatectomy for Recurrent Prostate Cancer: A Systematic Review (French ccAFU). Cancers (Basel). 2023 Nov 20;15(22):5485. doi: 10.3390/cancers15225485. PMID: 38001745 

Tsai MY, Lin CT, Chiang PH, Chiang PH, Chiang PC. ASO Author Reflections: High-Intensity Focused Ultrasound will Become the Routine Practice for Treatment of Localized Prostate Cancer. Ann Surg Oncol. 2023 Dec;30(13):8786-8787. doi: 10.1245/s10434-023-14297-3. Epub 2023 Sep 25. PMID: 37749406 

Tsai MY, Lin CT, Chiang PH, Chiang PH, Chiang PC. High-Intensity Focused Ultrasound (Sonablate®) for Prostate Cancer: Preliminary Outcomes in Taiwan. Ann Surg Oncol. 2023 Dec;30(13):8764-8769. doi: 10.1245/s10434-023-14250-4. Epub 2023 Sep 11. PMID: 37697133 

Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ, Polascik TJ. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023 Dec;84(6):547-560. doi: 10.1016/j.eururo.2023.06.013. Epub 2023 Jul 5. PMID: 37419773 

Ayerra Perez H, Barba Abad JF, Extramiana Cameno J. An Update on Focal Therapy for Prostate Cancer. Clin Genitourin Cancer. 2023 Dec;21(6):712.e1-712.e8. doi: 10.1016/j.clgc.2023.04.013. Epub 2023 May 3. PMID: 37258359 

Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, Allen C, Moore CM. Prostate Imaging after Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023 Dec;6(6):629-634. doi: 10.1016/j.euo.2023.04.007. Epub 2023 May 18. PMID: 37210343 

Pan Y, Wang S, Zhou H, Niu S, Liu X. Endoscopic Resection Improved High-Intensity Focused Ultrasound Ablation Outcomes for Prostate Cancer: A Meta-Analysis of Comparative Studies. Urol J. 2023 Oct 23;20(5):289-298. doi: 10.22037/uj.v20i.7378. PMID: 37330689 

Light A, Peters M, Reddy D, Kanthabalan A, Otieno M, Pavlou M, Omar R, Adeleke S, Giganti F, Brew-Graves C, Williams NR, Emara A, Haroon A, Latifoltojar A, Sidhu H, Freeman A, Orczyk C, Nikapota A, Dudderidge T, Hindley RG, Virdi J, Arya M, Payne H, Mitra AV, Bomanji J, Winkler M, Horan G, Moore C, Emberton M, Punwani S, Ahmed HU, Shah TT. External validation of a risk model predicting failure of salvage focal ablation for prostate cancer. BJU Int. 2023 Nov;132(5):520-530. doi: 10.1111/bju.16102. Epub 2023 Jun 29. PMID: 37385981 

Parry MG, Sujenthiran A, Nossiter J, Morris M, Berry B, Nathan A, Aggarwal A, Payne H, van der Meulen J, Clarke NW. Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound. BJU Int. 2023 Nov;132(5):568-574. doi: 10.1111/bju.16122. Epub 2023 Jul 25. PMID: 37422679 

Mattlet A, Limani K, Alexandre P, Hawaux E, Abou Zahr R, Aoun F, Diamand R. External validation of biochemical recurrence definition to predict oncologic outcomes following focal therapy for localized prostate cancer using high intensity focused ultrasound. Prostate. 2023 Dec;83(16):1564-1571. doi: 10.1002/pros.24614. Epub 2023 Aug 13. PMID: 37574824 

Shoji S, Naruse J, Oda K, Kuroda S, Umemoto T, Nakajima N, Hasegawa M, Mukasa A, Koizumi N, Miyajima A. Current status and future outlook of ultrasound treatment for prostate cancer. J Med Ultrason (2001). 2023 Oct 3. doi: 10.1007/s10396-023-01368-x. PMID: 37787881 

Kaufmann B, Raess E, Schmid FA, Bieri U, Scherer T, Elleisy M, Donati OF, Rupp NJ, Moch H, Gorin MA, Mortezavi A, Eberli D. Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial. BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213. PMID: 37897088 

Tsai MY, Lin CT, Chiang PH, Chiang PH, Chiang PC. High-Intensity Focused Ultrasound (Sonablate®) for Prostate Cancer: Preliminary Outcomes in Taiwan. Ann Surg Oncol. 2023 Sep 11. doi: 10.1245/s10434-023-14250-4. PMID: 37697133 

Séguier D, Villers A, Olivier J. Standardized reports of focal-HIFU results is paramount: a closer look at the Duwe et al.’s cohort on focal HIFU for localized prostate cancer. World J Urol. 2023 Sep 15. doi: 10.1007/s00345-023-04567-w. PMID: 37714967 

Jung G, Kim JK, Oh JJ, Lee S, Byun SS, Hong SK, Lee H. Partial gland ablation using high-intensity focused ultrasound versus robot-assisted radical prostatectomy: a propensity score-matched study. Prostate Int. 2023 Sep;11(3):134-138. doi: 10.1016/j.prnil.2022.12.001. Epub 2022 Dec 17. PMID: 37745903 

Tsai MY, Lin CT, Chiang PH, Chiang PH, Chiang PC. ASO Author Reflections: High-Intensity Focused Ultrasound will Become the Routine Practice for Treatment of Localized Prostate Cancer. Ann Surg Oncol. 2023 Sep 25. doi: 10.1245/s10434-023-14297-3. PMID: 37749406 

Mäkelä P, Anttinen M, Wright C, Sainio T, Boström PJ, Sequeiros RB. Evolution of non-perfused volume after transurethral ultrasound ablation of prostate: A retrospective 12-month analysis. Eur J Radiol Open. 2023 Jul 6;11:100506. doi: 10.1016/j.ejro.2023.100506. eCollection 2023 Dec. PMID: 37456928 

Debard C, Margue G, Klein C, Rompré-Brodeur A, Marcq G, Bensadoun H, Robert G, Anidjar M, Bladou F. Oncological and functional results of focal treatment of localized prostate cancer with HIFU. [Original Title: Résultats oncologiques et fonctionnels du traitement focal du cancer de prostate localisé par HIFU.] Prog Urol. 2023 Sep 26:S1166-7087(23)00215-4. doi: 10.1016/j.purol.2023.09.012. PMID: 37770359 

Topoozian M, Calais J, Felker E, Sisk A, Gonzalez S, Lee SJ, Marks LS. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. Urol Case Rep. 2023 Jun 9;50:102461. doi: 10.1016/j.eucr.2023.102461. eCollection 2023 Sep. PMID: 37358989 

De Cillis S, Osman N, Guillot-Tantay C, Hervé F, Przydacz M, Tutolo M, Culha G, Geretto P, Cancrini F, Checcucci E, Phé V, Phé V. Urinary outcomes of new ultra-minimally invasive treatments for prostate cancers. Curr Opin Urol. 2023 Aug 23. doi: 10.1097/MOU.0000000000001123. PMID: 37609708 

Peters I, Hensen B, Glandorf J, Gutberlet M, Dohna M, Struckmann S, Kuczyk MA, Wacker F, Hellms S. First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study. BMC Urol. 2023 Aug 29;23(1):142. doi: 10.1186/s12894-023-01306-6. PMID: 37644453 

Khandwala YS, Soerensen SJC, Morisetty S, Ghanouni P, Fan RE, Vesal S, Rusu M, Sonn GA. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. 2023 Jul;9(4):584-591. doi: 10.1016/j.euf.2022.10.010. Epub 2022 Nov 10. PMID: 36372735 

Henderson RH, Bryant C, Nichols RC Jr, Mendenhall WM, Mendenhall NP. Local salvage of radiorecurrent prostate cancer. Prostate. 2023 Aug;83(11):1001-1010. doi: 10.1002/pros.24551. Epub 2023 May 7. PMID: 37150849 

Rosnitskiy PB, Tsysar SA, Karzova MM, Buravkov SV, Malkov PG, Danilova NV, Ponomarchuk EM, Sapozhnikov OA, Khokhlova TD, Schade GR, Maxwell AD, Wang YN, Kadrev AV, Chernyaev AL, Okhobotov DA, Kamalov AA, Khokhlova VA. Pilot ex vivo study on non-thermal ablation of human prostate adenocarcinoma tissue using boiling histotripsy. Ultrasonics. 2023 Aug;133:107029. doi: 10.1016/j.ultras.2023.107029. Epub 2023 May 7. PMID: 37207594 

Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, Pinto P, Ahmed HU, Gill I, Klotz L, Taneja SS, Emberton M, Lawrentschuk N, Wysock J, Feller JF, Crouzet S, Kumar M P, Seguier D, Adams ES, Michael Z, Abreu A, Jack Tay K, Ward JF, Shinohara K, Katz AE, Villers A, Chin JL, Stricker PD, Baco E, Macek P, Ahmad AE, Chiu PKF, Crawford ED, Rogers CG, Futterer JJ, Rais-Bahrami S, Robertson CN, Hadaschik B, Marra G, Valerio M, Chong KT, Kasivisvanathan V, Tan WP, Lomas D, Walz J, Guimaraes GC, Mertziotis NI, Becher E, Finelli A, Kasraeian A, Lebastchi AH, Vora A, Rosen MA, Bakir B, Arcot R, Yee S, Netsch C, Meng X, de Reijke TM, Tan YG, Regusci S, Benjamin TGR, Olivares R, Noureldin M, Bianco FJ, Sivaraman A, Kim FJ, Given RW, Dason S, Sheetz TJ, Shoji S, Schulman A, Royce P, Shah TT, Scionti S, Salomon G, Laguna P, Tourinho-Barbosa R, Aminsharifi A, Cathelineau X, Gontero P, Stabile A, Grummet J, Ledbetter L, Graton M, Stephen Jones J, Polascik TJ, Polascik TJ. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023 Jul 5:S0302-2838(23)02943-3. doi: 10.1016/j.eururo.2023.06.013. PMID: 37419773 

Parry MG, Sujenthiran A, Nossiter J, Morris M, Berry B, Nathan A, Aggarwal A, Payne H, van der Meulen J, Clarke NW. Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound. BJU Int. 2023 Jul 8. doi: 10.1111/bju.16122. PMID: 37422679 

Mäkelä P, Anttinen M, Wright C, Sainio T, Boström PJ, Sequeiros RB. Evolution of non-perfused volume after transurethral ultrasound ablation of prostate: A retrospective 12-month analysis. Eur J Radiol Open. 2023 Jul 6;11:100506. doi: 10.1016/j.ejro.2023.100506. eCollection 2023 Dec. PMID: 37456928 

Nicoletti R, Alberti A, Castellani D, Yee CH, Zhang K, Poon DMC, Chiu PK, Campi R, Resta GR, Dibilio E, Pirola GM, Chiacchio G, Fuligni D, Brocca C, Giulioni C, De Stefano V, Serni S, Gauhar V, Ng CF, Gacci M, Teoh JYC. Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review. Prostate Cancer Prostatic Dis. 2023 Jul 28. doi: 10.1038/s41391-023-00699-7. PMID: 37507479 

Heard JR, Naser-Tavakolian A, Nazmifar M, Ahdoot M. Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes. Prostate Cancer Prostatic Dis. 2023 Jun;26(2):218-227. doi: 10.1038/s41391-022-00501-0. Epub 2022 Mar 4. PMID: 35246609 

Ahn H, Hwang SI, Kim TM, Lee HJ, Choe G, Hong SK, Byun SS, Lee H. Diagnostic value of multiparametric MRI in detecting residual or recurrent prostate cancer after high-intensity focused ultrasound. Prostate Cancer Prostatic Dis. 2023 Jun;26(2):360-366. doi: 10.1038/s41391-022-00531-8. Epub 2022 May 28. PMID: 35643729 

Benidir T, Wood A, Lone Z, Schwen Z, Abouassaly R, Nguyen J, Olivares R, Weight CJ, Purysko AS. The Feasibility and Value of a Focal Therapy Multidisciplinary Tumor Board, Including Radiographic and Pathological Overreads in Refining the Selection for High Intensity Focused Ultrasound in Prostate Cancer Patients. Urol Pract. 2023 Jul;10(4):372-377. doi: 10.1097/UPJ.0000000000000400. Epub 2023 Mar 16. PMID: 37103528 

Pan Y, Wang S, Zhou H, Niu S, Liu X. Endoscopic Resection Improved High-Intensity Focused Ultrasound Ablation Outcomes for Prostate Cancer: A Meta-Analysis of Comparative Studies. Urol J. 2023 Jun 18. doi: 10.22037/uj.v20i.7378. PMID: 37330689 

Topoozian M, Calais J, Felker E, Sisk A, Gonzalez S, Lee SJ, Marks LS. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. Urol Case Rep. 2023 Jun 9;50:102461. doi: 10.1016/j.eucr.2023.102461. eCollection 2023 Sep. PMID: 37358989 

Light A, Peters M, Reddy D, Kanthabalan A, Otieno M, Pavlou M, Omar R, Adeleke S, Giganti F, Brew-Graves C, Williams NR, Emara A, Haroon A, Latifoltojar A, Sidhu H, Freeman A, Orczyk C, Nikapota A, Dudderidge T, Hindley RG, Virdi J, Arya M, Payne H, Mitra AV, Bomanji J, Winkler M, Horan G, Moore C, Emberton M, Punwani S, Ahmed HU, Shah TT. External validation of a risk model predicting failure of salvage focal ablation for prostate cancer. BJU Int. 2023 Jun 29. doi: 10.1111/bju.16102. PMID: 37385981 

Duwe G, Boehm K, Haack M, Sparwasser P, Brandt MP, Mager R, Tsaur I, Haferkamp A, Höfner T. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol. 2023 May;41(5):1293-1299. doi: 10.1007/s00345-023-04352-9. Epub 2023 Mar 15. PMID: 36920492 

Chen X, Cvetkovic D, Chen L, Ma CM. An in-vivo study of the combined therapeutic effects of pulsed non-thermal focused ultrasound and radiation for prostate cancer. Int J Radiat Biol. 2023 May 19:1-8. doi: 10.1080/09553002.2023.2214204. PMID: 37191462 

Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, Allen C, Moore CM. Prostate Imaging after Focal Ablation (PI-FAB): A Proposal for a Scoring System for Multiparametric MRI of the Prostate After Focal Therapy. Eur Urol Oncol. 2023 May 18:S2588-9311(23)00083-4. doi: 10.1016/j.euo.2023.04.007. PMID: 37210343 

Ayerra Perez H, Barba Abad JF, Extramiana Cameno J. An Update on Focal Therapy for Prostate Cancer. Clin Genitourin Cancer. 2023 May 3:S1558-7673(23)00101-5. doi: 10.1016/j.clgc.2023.04.013. PMID: 37258359 

Duan H, Ghanouni P, Daniel B, Rosenberg J, Davidzon GA, Aparici CM, Kunder C, Sonn GA, Iagaru A. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High-Intensity Focused Ultrasound Therapy. J Nucl Med. 2023 Apr;64(4):592-597. doi: 10.2967/jnumed.122.264783. Epub 2022 Nov 3.

Sonn G, Khandwala Y. Reply to Carmen Gravina, Riccardo Lombardo, and Cosimo De Nunzio’s Letter to the Editor re: Yash S. Khandwala, Simon John Christoph Soerensen, Shravan Morisetty, et al. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. In press. Eur Urol Focus. 2023 Apr 1:S2405-4569(23)00087-1. doi: 10.1016/j.euf.2023.03.019.

Habashy D, Reddy D, Peters M, Shah TT, van Son M, van Rossum P, Tanaka MB, Cullen E, Engle R, McCracken S, Greene D, Hindley RG, Emara A, Nigam R, Orczyk C, Shergill I, Persad R, Virdi J, Moore CM, Arya M, Winkler M, Emberton M, Ahmed HU, Dudderidge T. Evaluation of Outcomes Following Focal Ablative Therapy for Treatment of Localized Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-Year Experience. J Urol. 2023 Apr 4:101097JU0000000000003443. doi: 10.1097/JU.0000000000003443.

Meyer L, Bohlscheid A, Lemmer O, van de Plas J, Leboutte F, Hadaschik BA, Neisius A, Willinek WA. MR-Guided Transurethral Ultrasound Ablation of Prostate Cancer: Initial Experience of Monitoring Tumor Response by Dynamic Apparent Diffusion Coefficient Measurements at 3.0 T. Urol Int. 2023 Apr 18:1-9. doi: 10.1159/000529873.

Ghoreifi A, Kaneko M, Peretsman S, Iwata A, Brooks J, Shakir A, Sugano D, Cai J, Cacciamani G, Park D, Lebastchi AH, Ukimura O, Bahn D, Gill I, Abreu AL. Patient-reported Satisfaction and Regret Following Focal Therapy for Prostate Cancer: A Prospective Multicenter Evaluation. Eur Urol Open Sci. 2023 Feb 18;50:10-16. doi: 10.1016/j.euros.2023.02.003. eCollection 2023 Apr.

Mäkelä P, Wright C, Anttinen M, Boström PJ, Blanco Sequeiros R. Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers. Acta Radiol. 2023 Mar;64(3):1228-1237. doi: 10.1177/02841851221108292. Epub 2022 Jun 24.

Ghai S, Perlis N. Beyond the AJR: MRI-Guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer. AJR Am J Roentgenol. 2023 Apr;220(4):610. doi: 10.2214/AJR.22.28413. Epub 2022 Aug 24.

Westhoff N, Ernst R, Kowalewski KF, Derigs F, Neuberger M, Nörenberg D, Popovic ZV, Ritter M, Stephan Michel M, von Hardenberg J. Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial. Eur Urol Focus. 2023 Mar;9(2):283-290. doi: 10.1016/j.euf.2022.10.006. Epub 2022 Nov 4.

Duwe G, Boehm K, Haack M, Sparwasser P, Brandt MP, Mager R, Tsaur I, Haferkamp A, Höfner T. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected. World J Urol. 2023 Mar 15. doi: 10.1007/s00345-023-04352-9.

Koelker M, Labban M, Frego N, Meyer CP, Salomon G, Lipsitz SR, Withington J, Moore CM, Tempany CM, Tuncali K, George A, Kibel AS, Trinh QD, Cole AP. Contemporary patterns of local ablative therapies for prostate cancer at United States cancer centers: results from a national registry. World J Urol. 2023 Mar 17. doi: 10.1007/s00345-023-04354-7.

Gravina C, Lombardo R, De Nunzio C. Re: Yash S. Khandwala, Simon John Christoph Soerensen, Shravan Morisetty, et al. The Association of Tissue Change and Treatment Success During High-intensity Focused Ultrasound Focal Therapy for Prostate Cancer. Eur Urol Focus. In press. Eur Urol Focus. 2023 Mar 31:S2405-4569(23)00088-3. doi: 10.1016/j.euf.2023.02.012.

Click here for additional references from PubMed.

Video courtesy of SonaCare Medical

FDA Approved
International Approval
Clinical Trials